-
FDA to review Eisai’s Leqembi Iqlik sBLA for Alzheimer’s
27 Jan 2026 11:21 GMT
Eisai and Biogen have announced … with similar clinical and biomarker benefits. Safety profiles were also comparable … treatment for 18 months.
Eisai leads global development and submissions … responsibilities.
In November 2025, Eisai and Biogen announced the UK …
-
Eisai and Biogen’s subcutaneous Leqembi given FDA Priority Review for early Alzheimer’s
26 Jan 2026 13:17 GMT
Eisai and Biogen’s Supplemental Biologics … showed similar clinical and biomarker benefits and demonstrated a safety profile …
-
The Potential Impact of GLP-1 Receptor Agonists on Exacerbation Risk in Patients with COPD and Type 2 Diabetes: A Real-World Population-Based Observational Study
29 Jan 2026 21:00 GMT
… have demonstrated cardiovascular and kidney benefits beyond glycemic control.5 Emerging … , Belus, Boehringer Ingelheim, Covis, Eisai, GlaxoSmithKline, Idorsia, Merck Frosst, Moderna … peptide-1 receptor agonists may benefit cardiopulmonary outcomes in patients …
-
With CMS’s New List of Meds for Drug Price Negotiation, Analyst Sees Small Financial Hit to Pharmas
29 Jan 2026 01:20 GMT
… consider factors such as clinical benefit and impact to patients, including … costs to insurers and pharmacy benefit managers (PBMs). The group also … — breast cancer, Novartis
Lenvima — cancer, Eisai and Merck
Orencia — inflammatory disorders …
-
<![CDATA[CMS Announces 15 Drugs for Third Cycle of Medicare Drug Price Negotiation Program]]>
28 Jan 2026 20:05 GMT
… (ribociclib; Novartis)
Lenvima (Lenvatinib mesylate; Eisai Co)
Orencia (abatacept; Bistol Myers … the selected drug’s clinical benefit, evidence about alternative treatments, and …
-
RET Fusion Targeted Therapies Market Set for Robust Growth by 2034 Amid Precision Oncology Shift | DelveInsight
27 Jan 2026 00:50 GMT
… is designed to determine therapeutic benefit across these molecularly defined subpopulations … ), Takeda, Ambrx, Daiichi Sankyo, Merck, Eisai, Bristol-Myers Squibb, Sanofi, NBE …
-
Leqembi® Iqlik™ (lecanemab-irmb) supplemental Biologics License Application regarding subcutaneous starting dose granted Priority Review by the US FDA
26 Jan 2026 03:25 GMT
… and similar clinical and biomarker benefits. SC administration demonstrated a safety … a long-term collaboration with Eisai regarding the development and commercialization … and commercialization agreement for lecanemab. Eisai is responsible for the clinical …
-
FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease under Priority Review
25 Jan 2026 23:30 GMT
… similar clinical and biomarker benefits. SC administration demonstrated a … for ARIA.
Consider the benefit of LEQEMBI for the … (LEQEMBI); the potential benefits, safety and efficacy of … benefits and potential of Biogen's collaboration arrangements with Eisai …
-
Endoscopic Examination and Long-Term Use of Proton Pump Inhibitors for Gastroesophageal Reflux Disease Treatment in Japan
23 Jan 2026 21:28 GMT
… and safe, however the risk-benefit balance should be considered for … remuneration from AstraZeneca K.K., Eisai Co., Ltd., Daiichi Sankyo Co … , August 2024. (in Japanese).
10. Eisai Co. Ltd. Pariet package insert …
-
Regulatory tracker: FDA sets decision date for Summit's PD-1xVEGF bid
02 Jan 2026 18:47 GMT
… ivonescimab has shown a consistent benefits in U.S. and Chinese … FDA has accepted Biogen and Eisai’s application for Alzheimer’s … to mount a patient survival benefit in the second-line indication …
About
© 1995-2026